Latest selective internal radiation therapy recommendations from EU proctors by Maleux, Geert
Latest SIRT recommendations from EU proctors 
Geert Maleux* 
University Hospitals Leuven, Belgium 
*Address for correspondence: Geert Maleux MD, PhD, Department of Radiology, University 
Hospitals Leuven, Herestraat 49, B3000 Leuven, Belgium 
 
1.Introduction to the training, evaluation and certification programme   
Proctors are suitably qualified physicians or clinicians, mostly interventional radiologists with 
extensive experience in selective internal radiation therapy (SIRT) using yttrium-90 (90Y) resin 
microspheres (SIR-Spheres microspheres, Sirtex Medical Ltd, Sydney, Australia), who have been 
contracted to act as trainers on behalf of Sirtex. 
The Training, Evaluation and Certification programme is consistent with the US Nuclear Regulatory 
Commission (NRC) guidelines that require a new authorised user to attend three training sessions 
delivered by either a Sirtex representative or trained physician proctor.  After three procedures, the 
proctor reviews the centre’s procedures to confirm that SIRT is being safely and effectively delivered 
since the outcome for patients is almost wholly determined by the skill of the interventional 
radiologist in performing this procedure. 
For the first SIRT procedure, the institute is required to send pre-treatment patient data to the proctor 
at least 5 days before the treatment date including: the patient‘s history on prior chemotherapy 
/biological therapy, prior abdominal surgery, functional status and physical examination data (blood 
test results, imaging results, mapping arteriograms, technetium-99m macroaggregated albumin [99mTc-
MAA] lung shunt study results and intended treatment plan).   In accordance with established 
guidelines from the peer-reviewed medical literature, it is important that the interventional radiologist 
who performs the SIRT procedure also performs the baseline mapping angiogram, thereby ensuring 
continuity of patient care and better training. 
2. Recommended procedures for generating mapping angiograms 
When CT angiography is available it should be reviewed prior to undertaking the mapping 
angiography to assist in detecting anatomy and the need for selective angiography (including the 
superior mesenteric artery and celiac axis) [1].  The mapping procedures should be conducted using 
an automated pump injection in order to identify not only the right and left hepatic arteries, but also 
the gastric arteries and any other accessory vessels, which may need to be coil embolised to ensure the 
safe administration of 90Y-resin microspheres. Suggested arterial contrast injection rates and volumes 
(Table 1) should be individualised according to the patient and vessel caliber with filming carried out 
into the late venous phase.  When injecting approximately 4 mCi of 99mTc-MAA, the catheter tip must 
be positioned in the same place as intended for the injection of the 90Y-resin microspheres.  Within 
one hour of the 99mTc-MAA injection, planar scintigraphic imaging should be performed with regions 
of interest drawn around the lungs and the liver and the counts for each region measured [2].  Early 
scintigraphic imaging is essential for ensuring the accurate assessment of lung shunting (since shunt 
fractions that could result in > 25Gylung radiation dose may exclude the patient from SIRT 
treatment).  Importantly, the 99mTc-MAA study should be performed within 4 weeks prior to the 
planned SIRT treatment date and generally not on the same day as the SIRT procedure. Combining 
90Y-resin microspheres and 99mTC-MAA, may however be feasible in appropriately selected patients.  
For example, investigators from the University Hospital Bonn combined 90Y-resin microspheres with 
a simultaneous second test angiogram of another lobe or segments in the same session in six patients 
[3].  In this study, immediate post-therapeutic 99m Tc-MAA SPECT/CT showed only the distribution 
of 99mTc-MAA without any detectable 90Y-Bremsstrahlung SPECT/CT; while a post-therapeutic 
Bremsstrahlung SPECT/CT scan conducted 48 hours later could be performed without any 99mTc-
MAA contamination. 
It is clear from the experience of the Nuclear Medicine Physicians from University Hospital Bonn that 
SPECT/CT has much higher sensitivity and specificity than planar or non-attenuation-corrected 
SPECT for the assessment of extrahepatic MAA deposition [4].  In pre-SIRT planning, 99mTc-MAA 
SPECT/CT is the most valuable technique for identifying extrahepatic visceral sites at risk for post-
SIRT complications.  In these patients, further coil embolisation may be necessary; alternatively the 
catheter can be placed distal to the extrahepatic artery in order to ensure the safe delivery of SIRT 
(Figure 1).  For the cystic arteries, however, coil embolisation is not considered necessary because the 
respective risks of ischaemic injury or radiation injury to the gallbladder are similar with and without 
embolisation (~5%). 
 
3. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake 
Response to SIRT was found to be independent of the degree of 99mTc-MAA uptake [5]. Therefore, it 
is the view of the proctors that SIRT should not be withheld from patients with colorectal liver 
metastases lacking intratumoral 99mTc-MAA accumulation. 
 
4. Dosimetry 
The calculation of the activity to be delivered should be discussed  by the radiologist and the nuclear 
medicine physician during the multidisciplinary team meeting.  Some important practice points to 
consider are as follows: 
 The point of injection (tip of the catheter position) and the activity delivered must  be marked 
on the scans for follow-up 
 Body surface area (BSA) model is the preferred method of calculation of the prescribed 
activity 
 Tumour volume should be calculated (not estimated) from CT  
 Consider reduction in prescribed activity by 20-30% for the following patients: 
 Heavily pre-treated 
 Cirrhotics  
 5-10% tumour burden (high tumour burden : case dependent)  
 Small livers (<1200-1500 cc)[6]  
These recommendations are based on recent study from the Pamplona group [6] who showed that the 
incidence of Radioembolisation (SIRT) Induced Liver Disease (REILD) was reduced by lowering the 
treatment intensity in patients who had received prior exposure to cancer chemotherapy, cirrhosis or a 
reduced liver and/or tumour volume.  By contrast, treatment intensity could be safely increased with 
more selective SIRT with a radical intent.  In all patients, 600 mg/d of ursodeoxicolic acid was given 
for 2 months post-SIRT [6]. 
 
5. Peri-procedural care 
The following recommendations [7] have been published: 
• Proton Pump Inhibitor (PPI) must be given at least  for 1 week after SIRT 
• better: starting 1 week before and given for 4 weeks after SIRT 
• Pain medication is should be given either before or during the SIRT procedure 
• Corticosteroids may be given 24 hours before and for a minimum of 1 week after the 
treatment 
• or better: 8 mg qd for 4 weeks and 4 mg qd for another 4 weeks 
• Anti-emetics are usually commenced on the morning of the day of SIRT treatment  
• Antibiotics are not recommended  unless the patient has had biliary surgery, prior stent 
implantation or a bile duct obstruction 
• Carcinoid crisis prophylaxis: short-acting somatostatin analogue should be considered for the 
prevention of carcinoid crisis 
• 2x-300 mg Ursodeoxycholicacid for (4-) 8 weeks   
In addition, administration of 300 mg sodium perchlorate (NaCl04)(20-30 gtt) min. 2 – 4 hours before 
application of 99mTc-MAA  is recommended in order to inhibit the Na-I-symporter protein in the 
gastric mucosa, thereby making it easier to discriminate between gastric / extrahepatic MAA and 
gastric accumulation of free pertechnetate [8]. 
 
6. General principles for repeated SIRT  
The following general principles should be applied when considering repeat SIRT [7]: 
 Time interval from 1st or most recent 90Y treatment should be at least 12 weeks (taking into 
account the typical tumour response by RECIST or WHO between 10-14 weeks post SIRT ) 
 A more selective treatment strategy should be considered so segments of the liver can be 
spared radiation during subsequent treatment  
 Interval therapies since last SIRT can impact on liver tolerance and may lead to either a 
reduced activity planned or avoidance of a lobe or segment for retreatment.  
 Trends in functional liver reserve parameters (AP, GOT, GPT, bilirubin, albumin) over past 3 
months are helpful   
 
7. The Coldwell “Sandwich” delivery technique 
Today, it is recommended that 90Y-resin microspheres are injected using the Coldwell “Sandwich” 
Delivery Technique which involves putting the aliquot of 90Y-resin microspheres into the line first 
followed by 1 mL of sterile water then 1-2 mL of contrast (full strength).  While using fluoroscopy, 
the entire content should  be pulsed through the microcatheter using a 20 mL syringe constantly so 
that the pulsing creates a turbulent flow for the more even delivery of the the microspheres.  Once the 
contrast is observed (indicating that the microspheres have been delivered), the pressure on the sterile 
water syringe can be increased to check the flow in the treated artery. 
 The advantage of this technique is that: the catheter tip is watched continuously so that it does not 
inadvertently move into another artery; the flow is seen at each injection and so there is no need to do 
a true arteriogram that wastes contrast and time; and finally, the delivery is safer since the operator 
knows immediately when the flow slows down. 
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Table 1.  Suggested Arterial rates and volumes recommended for generating mapping angiograms 
Vessel  Injection Rate  Volume  Acquisition 
SMA    
Celiac axis  5-7cc/sec 20-30cc 2-3fps/12s-1fps/20s  
Proper HA  4cc/sec  12cc  2-3fps/10s-1fps/20s  
Replaced HA  2-4cc/sec  8-16cc 2-3fps/10s-1fps/20s  
Right or left HA 1-3cc/sec  4-12cc 2-3fps/10s-1fps/20s 
 Liu D et al. J Vasc Interv Radiol 2005;16:911-935  
   
Figure 1.  Procedure for identifying extrahepatic visceral sites at risk for post-SIRT complications 
 
 
 
 
